ARMP
Price
$1.29
Change
-$0.03 (-2.27%)
Updated
Apr 4, 04:20 PM (EDT)
Capitalization
47.76M
34 days until earnings call
SRRK
Price
$26.98
Change
-$3.71 (-12.08%)
Updated
Apr 4, 04:31 PM (EDT)
Capitalization
2.91B
34 days until earnings call
Ad is loading...

ARMP vs SRRK

Header iconARMP vs SRRK Comparison
Open Charts ARMP vs SRRKBanner chart's image
Armata Pharmaceuticals
Price$1.29
Change-$0.03 (-2.27%)
Volume$1K
Capitalization47.76M
Scholar Rock Holding
Price$26.98
Change-$3.71 (-12.08%)
Volume$5.77K
Capitalization2.91B
ARMP vs SRRK Comparison Chart
Loading...
ARMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARMP vs. SRRK commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARMP is a Hold and SRRK is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ARMP: $1.32 vs. SRRK: $30.70)
Brand notoriety: ARMP and SRRK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARMP: 530% vs. SRRK: 100%
Market capitalization -- ARMP: $47.76M vs. SRRK: $2.91B
ARMP [@Biotechnology] is valued at $47.76M. SRRK’s [@Biotechnology] market capitalization is $2.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARMP’s FA Score shows that 0 FA rating(s) are green whileSRRK’s FA Score has 0 green FA rating(s).

  • ARMP’s FA Score: 0 green, 5 red.
  • SRRK’s FA Score: 0 green, 5 red.
According to our system of comparison, SRRK is a better buy in the long-term than ARMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARMP’s TA Score shows that 4 TA indicator(s) are bullish while SRRK’s TA Score has 4 bullish TA indicator(s).

  • ARMP’s TA Score: 4 bullish, 5 bearish.
  • SRRK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SRRK is a better buy in the short-term than ARMP.

Price Growth

ARMP (@Biotechnology) experienced а -20.00% price change this week, while SRRK (@Biotechnology) price change was -7.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.86%. For the same industry, the average monthly price growth was -16.74%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

ARMP is expected to report earnings on May 08, 2025.

SRRK is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-10.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRRK($2.91B) has a higher market cap than ARMP($47.8M). ARMP (-28.649) and SRRK (-28.968) have similar YTD gains . ARMP has higher annual earnings (EBITDA): -31.21M vs. SRRK (-250.12M). SRRK has more cash in the bank: 437M vs. ARMP (17.1M). SRRK has less debt than ARMP: SRRK (65.1M) vs ARMP (140M). ARMP (0) and SRRK (0) have equivalent revenues.
ARMPSRRKARMP / SRRK
Capitalization47.8M2.91B2%
EBITDA-31.21M-250.12M12%
Gain YTD-28.649-28.96899%
P/E RatioN/AN/A-
Revenue00-
Total Cash17.1M437M4%
Total Debt140M65.1M215%
FUNDAMENTALS RATINGS
ARMP vs SRRK: Fundamental Ratings
ARMP
SRRK
OUTLOOK RATING
1..100
5355
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
10074
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9435
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SRRK's Valuation (66) in the Biotechnology industry is in the same range as ARMP (81). This means that SRRK’s stock grew similarly to ARMP’s over the last 12 months.

SRRK's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as ARMP (100). This means that SRRK’s stock grew similarly to ARMP’s over the last 12 months.

SRRK's SMR Rating (98) in the Biotechnology industry is in the same range as ARMP (100). This means that SRRK’s stock grew similarly to ARMP’s over the last 12 months.

SRRK's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for ARMP (94). This means that SRRK’s stock grew somewhat faster than ARMP’s over the last 12 months.

ARMP's P/E Growth Rating (90) in the Biotechnology industry is in the same range as SRRK (100). This means that ARMP’s stock grew similarly to SRRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARMPSRRK
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 18 days ago
85%
Bullish Trend 19 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
ARMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCTCX40.40N/A
N/A
Goldman Sachs US Tax-Managed Eq C
EMRYX13.93N/A
N/A
VanEck Emerging Markets Y
OAZGX34.14N/A
N/A
Oakmark Global R6
PHLOX9.78N/A
N/A
Philotimo Focused Growth and Income
RIDHX24.95-0.52
-2.04%
American Funds Income Fund of Amer R5E